BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raschi E, Caraceni P, Poluzzi E, De Ponti F. Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19? Expert Opin Drug Saf 2020;19:1367-9. [PMID: 32840116 DOI: 10.1080/14740338.2020.1812191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Elahi R, Karami P, Heidary AH, Esmaeilzadeh A. An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19). International Immunopharmacology 2022;105:108536. [DOI: 10.1016/j.intimp.2022.108536] [Reference Citation Analysis]
2 Wang X, Lei J, Li Z, Yan L. Potential Effects of Coronaviruses on the Liver: An Update. Front Med (Lausanne) 2021;8:651658. [PMID: 34646834 DOI: 10.3389/fmed.2021.651658] [Reference Citation Analysis]
3 Gatti M, Turrini E, Raschi E, Sestili P, Fimognari C. Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. Pharmaceuticals (Basel) 2021;14:738. [PMID: 34451835 DOI: 10.3390/ph14080738] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
4 Sodeifian F, Seyedalhosseini ZS, Kian N, Eftekhari M, Najari S, Mirsaeidi M, Farsi Y, Nasiri MJ. Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review. Front Med (Lausanne) 2021;8:731436. [PMID: 34616757 DOI: 10.3389/fmed.2021.731436] [Reference Citation Analysis]